Anthony Taglienti, MD
Plastic and Reconstructive Surgery · New Hyde Park, NYNPI 1386879880
Payments from drug & device makers
Across 33 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$242
- Johnson & Johnson$194
- AbbVie$116
- Lilly USA, LLC$70
- Organon$56
- UCB, Inc.$32
- plus $155 from 8 others
What the payments were for
- Food & beverage$865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 3 | $242 |
| Johnson & Johnson | 10 | $194 |
| AbbVie | 5 | $116 |
| Lilly USA, LLC | 3 | $70 |
| Organon | 2 | $56 |
| UCB, Inc. | 2 | $32 |
| Incyte Corporation | 1 | $26 |
| Sanofi | 1 | $25 |
| Pfizer | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| Biofrontera Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Glenmark Therapeutics Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$165
How this compares
$865 in reported general payments places this provider in the 40th percentile of 219 plastic and reconstructive surgery providers in New York.
See all plastic and reconstructive surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 33 | $853 |
| Mupirocin | 54 | $354 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $172 |
| Methylprednisolone | 18 | $118 |
| Cefadroxil | 20 | $85 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in New Hyde Park
- James BradleyNew Hyde Park$306K
- Thomas DavenportGarden City$2.8M
- Babak MehraraNew York$756K
- David FuntWoodmere$393K
- Howard LangsteinRochester$350K
- Lawrence BassNew York$341K
- Robert GrantNew York$207K
- Christine RohdeNew York$180K
- Graham SchwarzNew York$125K
- Steven LevineNew York$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.